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ABSTRACT - Proliposomes are stable drug carrier systems designed to form liposomes upon addition of an 
aqueous phase. In this review, current trends in the use of supercritical fluid (SCF) technologies to prepare 
proliposomes are discussed. SCF methods are used in pharmaceutical research and industry to address 
limitations associated with conventional methods of pro/liposome fabrication. The SCF solvent methods of 
proliposome preparation are eco-friendly (known as green technology) and, along with the SCF anti-solvent 
methods, could be advantageous over conventional methods; enabling better design of particle morphology 
(size and shape). The major hurdles of SCF methods include poor scalability to industrial manufacturing which 
may result in variable particle characteristics. In the case of SCF anti-solvent methods, another hurdle is the 
reliance on organic solvents. However, the amount of solvent required is typically less than that used by the 
conventional methods. Another hurdle is that most of the SCF methods used have complicated manufacturing 
processes, although once the setup has been completed, SCF technologies offer a single-step process in the 
preparation of proliposomes compared to the multiple steps required by many other methods. Furthermore, 
there is limited research into how proliposomes will be converted into liposomes for the end-user, and how 
such a product can be prepared reproducibly in terms of vesicle size and drug loading. These hurdles must be 
overcome and with more research, SCF methods, especially where the SCF acts as a solvent, have the potential 
to offer a strong alternative to the conventional methods to prepare proliposomes.   
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
____________________________________________________________________
 
INTRODUCTION 
 
Liposomes are spherical nano/micro-sized 
spherical vesicles composed of an aqueous core 
enclosed by one or more phospholipid layers. 
Liposomes are similar in structure to cells in the 
body, and are considered to be non-toxic, 
biodegradable, and biocompatible. Since the 
discovery of liposomes by Bangham, et al., in the 
mid-1960 (1) a substantial research field has 
spawned with liposomes being developed as novel 
drug delivery systems (DDS). Proliposomes are 
fine granules composed of bioactive and 
phospholipids, and upon hydration with aqueous 
phase prior to administration, they are converted 
into liposomes. This solid state formulation offers 
the advantage of being more physically and 
chemically stable on storage than liposomes (2, 3). 
Proliposomes have been used to form DDS for the 
anti-cancer agents such as doxorubicin HCL 
(Myocet by Zeneus Pharma, Oxford, UK) (4, 5) 
and for fungal infections such as amphotericin B 
(AmBisome by Gilead Sciences, Foster City, 
California, USA) (6). Since being introduced by 
Payne, et al. in the 1980s (3), many methods have 
been developed to make proliposomes with 
pharmaceutical application. The final product, 
however, is that to form a liposome from 
proliposome solid materials, hydration or 
reconstitution is required to achieve this 
transformation. There are a several ways to form 
liposomes from proliposomes, such as using an 
aqueous buffer (7) with stirring or heating, as 
shown in Fig 1 (8, 9). The commercial products 
come with vials of proliposomes and buffer, and 
for the anti-fungal product, the excipients include 
sodium < 0.5 mmol/vial and sucrose 900 mg/vial. 
A simple reconstitution method prior to 
administration is required so that patients can 
readily be given their medicines by health 
practitioners such as doctors and nurses, or if 
possible where a patient themselves could prepare 
liposomes. Perhaps the latter scenario would be 
only possible if the route of administration did not 
involve the use of parenteral application e.g. an 
oral formulation.  
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Figure 1. Possible steps to form liposomes from solid proliposomes. SCF-EPCS solid proliposomes are shown in the 
SEM image from Reference (8). In the liposome, the possible locations for a lipophilic drug are among the alkyl tails of 
the phospholipids. Rehydrated liposomes prepared using a SCF method are shown in the microscopic images from 
Reference (9). Reference (9)B, enlargement of a liposome (8, 9). EPCS, phosphatidylcholine from egg lecithin; SEM, 
scanning electron microscopy. Copyright (2015) Reference (8) reproduced with permission from Int J Nanomed 
2014:9(1) Pages 5079 - 5091 [Dove Medical Press] and Reference (9) reproduced with permission from J of Supercritical 
Fluids 2012:72 Pages 125 – 133 [Elsevier]. 
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The special characteristics of liposomes make 
them a highly versatile DDS as one or more active 
pharmaceutical ingredients (APIs) can be loaded 
into one system, with hydrophilic APIs 
encapsulated in the aqueous core and lipophilic 
APIs residing within the lipid bi-layer (10). As 
DDS, liposomes can facilitate the delivery of drugs 
via different routes of administration, such as 
parenteral, dermal and transdermal, and pulmonary 
routes. In each case, the liposomal carrier systems 
play different roles such as solubliser, skin 
penetration enhancer, and sustained release system 
(11). Most importantly, liposomes  have the 
potential to confer the drug tumour-targeting 
property, enhancing the therapeutic outcome of 
anti-cancer drugs (12). Liposome encapsulation 
prevents the entrapped cytotoxic drugs from 
passive diffusion into non-targeted tissues leading 
to side effects (13). Selective tumour localization 
is further achieved through the enhanced 
permeability and retention (EPR) effect by 
exploiting the leaky vasculatures of the tumours 
(14). In this case liposomes must meet certain 
criteria, the least of which are; an effective size 
range (50 to 200 nm) (15), a relatively long plasma 
residence time (half-life > 6 h) to allow 
accumulation at the tumour site following 
extravasation through leaky tumour vasculature 
(16, 17). 
Designing liposomal DDSs is a challenging 
task with vesicle size, size distribution, 
morphology, and membrane composition all 
influencing performance. Furthermore, issues with 
the physical and chemical stability of liposomes 
can limit their use (2). Liposomes themselves can 
be physically unstable due to spontaneous and 
irreversible aggregation and fusion, which can be 
associated with a loss of captured active molecules. 
Chemical instabilities in constituent phospholipids 
due to hydrolysis and oxidation altering the 
functions of the drug delivery vehicle (18). In 
addition, the high cost of materials and typically 
tedious manufacturing processes which require 
multiple steps, which are time consuming and 
labour intensive and the use of organic solvents has 
limited development and manufacturing by the 
pharmaceutical industry (19, 20). Despite these 
drawbacks, liposomes remain a strong platform for 
future DDSs due to their versatility and proven 
efficacy (2). One way to address the stability 
drawbacks of liposomes is in the preparation of 
aqueous free proliposomes, or solid pre-liposomes, 
which can be simply converted to liposomes when 
required, prior to administration. There are several 
conventional methods reported to produce 
proliposomes, some of them are practically similar 
to the methods used to make liposomes such as the 
Bangham method followed by a solid-state 
preparation step, i.e. dehydration, see Table 1. 
As shown in Table 1, the conventional 
proliposome preparation methods usually require a 
substantial use of organic solvents. This 
shortcoming has two main implications, firstly the 
organic residue within the final product must be 
within strict levels set by regulators (good 
manufacturing practice, GMP), and secondly, the 
waste solvents must be discarded in such a way that 
the environmental impact is minimal complying 
with the further governmental regulations (37). 
The US Food and Drug Administration (FDA) and 
European Union (EU) have well established 
regulations on the use of organic solvents. In 2007, 
the EU implemented the legislation REACH 
(Registration, Evaluation, Authorisation and 
Restriction of Chemicals) with the intention to 
promote the use of alternative methods and 
chemicals in order to protect human health and the 
environment (37). An additional shortcoming with 
current proliposome preparation methods is the 
lengthy processing time to remove solvent due to 
the need for extra steps or sometimes requiring 
cryo-protectants. The use of organic solvents also 
brings regulatory hurdles, as the final products may 
contain organic residues (19, 30). 
To address the shortcomings of proliposomal 
production a propitious method is to use 
supercritical fluid (SCF) technologies (2, 38). In 
addition the conventional methods for preparation 
of proliposomes (Table 1) suffer from wide batch-
to-batch variability, do not produce vesicles with 
desirable particle size distribution (39, 40). The 
conventional methods have demonstrated the 
production of proliposomes but they have 
significant drawbacks that SCF based methods 
could address. 
In this review, current SCF methods to produce 
proliposomes are outlined, with the solvent 
methods listed first, followed by the anti-solvent 
SCF methods. The principles, advantages and 
disadvantages for each SCF method are 
highlighted, along with the typical characterisation 
studies performed. The key differences between 
methods will be discussed, to help identify the 
important factors of each SCF method described. 
Throughout this paper, the abbreviation PL is used 
to mean pro- or pre- liposomes. The literature 
search methodology involved the use of Medline 
and Scopus using the search terms: supercritical 
fluid, proliposome, and preliposome.  
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Table 1. Conventional preparation methods for liposomes and follow-on steps to form proliposomes. 
Method  Procedure 
(steps involved) 
Follow-on method/s to 
form solid state product 
(proliposomes from 
liposomes) 
Bangham; 
Also known as the hand-
shaken or the thin-film 
distribution on carrier (1, 
18, 21)  
1) Mixture of phospholipid  
and cholesterol dispersed in organic solvent 
2) Organic solvent removed by rotary evaporator 
3) Hydration of solid lipidic film prior to use 
 
Collect solid 
proliposomes after step 2 
Reverse-phase evaporation 
vesicles (REV) (22) 
As above for steps 1) and 2), then 
3) Lipidic film purged with nitrogen and re-dissolved in 
organic solvent 
4) Aqueous buffer introduced and organic solvent 
removed under continuous nitrogen 
Freeze-drying (23, 24), or 
fluid-bed drying (25), or 
spray-drying (26) 
Solvent injection 
(either with ethanol or 
ether) (27, 28) 
As above for step 1), then  2) Inject lipid solution into 
aqueous media to form liposomes 
One follow-up step from 
above (56-59) 
Detergent dialysis (29) 1) Mixture of phospholipid  
and cholesterol dispersed with detergent (forming 
micelles) 
2) Detergent removed by dialysis forming unilamellar 
liposomes 
3) Further possible step to reduce size, e.g. 
homogenisation 
 
 
One follow-up step from 
above (56-59) 
Effervescent (30-32) 1) Mixture of phospholipid  
and cholesterol dispersed in organic solvent 
2) Ethanol solution filtered through membrane, 
transferred and stirred in citric acid (5% w/v) for 30 min. 
3) Add into a carbonic acid monosodium salt solution 
(5% w/v) and stir until milk white suspension formed 
 
Freeze solution (-60° C) 
and lyophilize for 36 h 
and collect solid freeze-
dried product 
 
Heating method (33) 
 
1) Disperse lipids in water 
2) Heat ingredients in 3% glycerol to 120° C while 
stirring 
One follow-up step from 
above (56-59) 
Supercritical reverse phase 
evaporation (SCRPE) (34) 
1) Disperse lipids in scCO2/ethanol 
2) Inject aliquots of water into emulsion while stirring 
under SC conditions, then release pressure 
One follow-up step from 
above (56-59) 
Spray-drying (7) 1) Disperse lecithin and mannitol in chloroform 
2) Sonicate solution 
3) Spray-dry 
4) Hydrate in phosphate buffer saline by stirring for 45 
minutes 
 
Stop after step 3, to 
collect solid 
proliposomes 
Freeze-drying (35, 36) 
 
 
 
1) Disperse lipids with sucrose in tert-butyl alcohol and 
water 
2) Sterilise by filtration and fill into vials for freeze-
drying 
3) Freeze-dry: 3a) freeze at –40° C for 8 h, 3b) dry at 25° 
C for 48 hrs, and 3c) final drying at 25° C for 10 h 
4) Form liposomes by hydration 
 
 
Stop after step 3, to 
collect solid 
proliposomes 
 
 
Supercritical fluid technologies 
Supercritical fluid technologies are a relatively 
new field of research in pharmaceutical sciences 
and have a range of applications including 
extractions, chromatography, and particle 
formation. In the case of particle formation, which 
is where PLs preparation is a subcategory, the SCF 
is able to facilitate precipitation much faster than 
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in liquids. By rapidly exceeding the saturation 
solubility of a solute, through dilution and/or 
depressurisation, SCF processing enhances 
nucleation and crystal growth (41). The SCF 
technologies are able to yield nano-/micro- and 
regularly sized particles. SCFs themselves exist in 
the pressure-temperature curve above both critical 
temperature and critical pressure where the 
physico-chemical properties of the pseudo-state 
are intermediate between that of a gas and a liquid 
(Table 2). Specifically, SCFs exhibit higher 
diffusivity than a liquid but lower viscosity than a 
liquid, combining gas and liquid solvent properties 
together (Table 3).  
Supercritical fluid processing operates at mild 
and inert conditions making it possible to work 
with thermo-sensitive compounds including 
proteins (44, 45). The solvent power of the SCF 
means there is enormous potential to diminish or 
even eliminate the need for organic solvents (10, 
46), so SCF solvent technologies are GMP 
compliance ready, and can provide high quality 
products (47, 48). The solvent power of SCFs is 
superior to that of conventional solvents, which 
can improve the mixing of excipients and APIs to 
prepare solid or molecular dispersions (43). It is the 
SCF solvent methods that do not rely on organic 
solvents and the area which has the greatest 
potential and needs to be a focus of future research.  
The versatile properties of SCFs have been 
used to solubilize poorly-water soluble compounds 
which can be manipulated by changing the 
temperature and pressure during processing (30, 
49). Even a small change in pressure for instance, 
20 bar, can increase the solubility of a compound 
in the SCF by many fold. For example, the 
solubility of progesterone in supercritical CO2 
(scCO2) increases 4 times at 60° C when pressure 
is increased from 110 – 170 bar (50). As a solvent, 
the SCF state of carbon dioxide (CO2) is therefore 
superior to its liquid form due to this “solvent 
tunability property”. There are a range of different 
compounds that can be brought into the 
supercritical fluid state, Table 2 (42). As an 
example, CO2 is frequently used as a SCF due to 
its low critical temperature (31.5° C/90° F) and 
critical pressure of 73 bar (Figure 2).  
These relatively mild SCF forming properties 
helps the usability of CO2 for both polar and non-
polar API molecules, and allow for processing of 
thermo-sensitive compounds, both API and non-
API. Furthermore, CO2 is considered non-toxic, 
non-immunogenic, affordable, readily available, 
non-corrosive, stable across a wide range of 
temperatures and pressures. In terms of APIs with 
higher boiling points (most APIs would be 
considered non-volatile), which would normally be 
difficult dissolve without the use of an organic 
solvent or heat, can however be dissolved with 
scCO2 (13). 
 
Table 2. Critical properties of different compounds used in supercritical fluid technology (42). 
Compound Tc* (⁰C) Pc** (bar)  Note 
Ammonia 132.6 113 Green 
technology 
fluids 
Carbon dioxide 31.5 73 
Nitrogen -147 34 
Water 374.5 221 
Benzene 
Chlorotrifluoromethane  
289 
111.9 
49 
39 
 
 
Ethylene 9.3 51 
Ethane 32.5 49  
Methanol 240.6 79  
n-Propane 93.9 43  
Dimethyl ether 127 53  
*Tc = critical temperature; Pc** - critical pressure 
 
 
Table 3. General orders of magnitude of physical properties in three states of matter (43). 
State of matter 
Property 
Density × 102 (kg·m-3) Diffusivity × 10-3  (cm2·s-1) Viscosity × 10-4   (kg·m·s-1) 
Liquid 6 -16 0.002 - 2 2 – 30 
SCF (Pc: Tc) 2 – 5 0.7 0.1 – 0.3 
4Pc: Tc 4 – 9 0.2 0.3 – 0.9 
Gas 0.006 – 0.02 0.1 – 0.4 0.1 – 0.3 
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Furthermore, SCF technologies which rely on CO2 
are ‘green’ technologies (Table 2) because the gas 
collected is released back into the atmosphere, 
resulting in no net change in atmospheric CO2 
levels. Some SCFs require much higher 
temperatures and pressures for operation (e.g. the 
critical point of water is 647° C and 220 bar and for 
ammonia is 133° C and 113 bar) resulting in 
mechanical stresses on equipment and difficulty in 
maintaining safety standards (20).  Interestingly, 
SCFs can also act as an anti-solvent in order to 
rapidly precipitate out desired components. The 
supercritical anti-solvent process (SAS) and SAS-
derived processes, have been utilised to form 
proliposomes. These different SCF methods will 
be separately discussed for clarity in the following 
sections. 
 
Supercritical fluid methods for proliposome 
preparation 
Supercritical fluid technologies was firstly 
researched and established as an alternative to 
conventional methods to prepare proliposmes, by 
Magnan, et al in 2000 (38). Supercritical fluid 
technology enables precise control and 
manipulation of SCF solutions and suspensions 
during processing at the small scale using 
micrometer valves. The processing of a SCF 
involves the use of the desired temperature and 
pressure for a pre-determined time period. After 
SCF processing, the SCF is extracted by release of 
a valve, which can be opened slowly using 
graduations marked on the valves or rapidly, 
leaving well-defined proliposome particles. To 
date, a small number of SCF papers, as detailed in 
Table 4, have been used to produce proliposomes. 
It should be noted again, that the majority of the 
SCF methods used to produce proliposomes are 
anti-solvent, that is require organic solvent, 
whereas there are only two SCF solvent methods. 
It is the latter, SCF solvent methods which offer the 
best potential, even if only to avoid the use of any 
organic solvents and from a regulatory perspective 
this will be of significance. The SCF solvent 
methods are outlined first. Figure 3 shows the 
general rig assemblies for different supercritical 
fluid technologies. 
 
Particles from gas-saturated solution method 
(PGSS) 
Utilising a supercritical fluid as a co-solvent was 
first described by Graser, et al., to form particles 
from gas saturated solutions (PGSS) (60). This 
technique has since been researched modestly to 
produce solid-state proliposomes. By exploiting 
the ability of the SCF to diffuse into solute of a 
particular solution, this technique causes an 
expansion of solvent/co-solvent volume, resulting 
in significant reduction in solution viscosity and 
modifying melting points of the binary/ternary 
systems. With additional pumping of supercritical 
fluid into the system the pressure increases and a 
gas-saturated solution is produced. The general 
experimental setup of this method is shown in 
Figure 3D. This is different to the SAS methods, 
not only by way of the solvent effect, but also in 
that there is another chamber for the sample 
(bioactive/other ingredients in solution) to be pre-
loaded and this is known as the sample cylinder. 
The PGSS method also varies in the steps 
taken to complete a batch run. There are three main 
steps, the first is to prepare a simple, ideally 
solvent-free, homogenous solution (it could also be 
a suspension or emulsion), the second step includes 
mixing of the solution with the SCF to achieve a 
gas-saturated solution, and the final step is 
performed by mixing the solution with SCF further 
via a capillary where the mixture if subject to rapid 
atmospheric expansion. Here the SCF evaporates 
as a gas, leaving the precipitated microparticles in 
the precipitation chamber. This technique offers 
many advantages in terms of having a lower 
operating pressure compared to other SCF 
methods, no need to use organic solvent. The 
amount of carbon dioxide consumed is much lesser 
compared to previously outlined SAS methods and 
precipitated particles come with small size and 
narrow particle size distributions. It is important to 
note that the PGSS method has also been 
developed using the SCF as an anti-solvent to form 
a suspension. Both types of PGSS methods (one 
solvent, one other anti-solvent) have been 
researched for proliposome preparation, as 
follows; 
In a study by Varona, et al., PGSS method was 
applied to prepared proliposomes encapsulating 
natural antimicrobial and antiviral avandin oil, a 
volatile, easily degradable, and hydrophobic 
compound (54). In this study, an emulsion was 
prepared by adding phospholipid compound 
(lecithin) within different ratios of deionised water 
at 50º C, lavandin oil was then added gradually to 
obtain an emulsion. The emulsion was processed 
further to improve the homogeneity by means of a 
homogenizer to achieved fine suspended droplets. 
Once added to the sample SCF cylinder, scCO2 
was pumped in, resulting in sudden reduction in the 
viscosity of emulsion facilitating the forming of a 
new emulsion containing dissolved carbon dioxide 
into the dedicated precipitation chamber.  
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 Figure 2. Typical phase diagram for carbon dioxide. TP = triple point, CP = critical point, SCF = supercritical fluid. 
 
 
Consequently, precipitated small fine dry particles 
form on expansion. This method produced 
spherical micro-sized proliposomes which under 
hydration formed mulilamellar liposomes with size 
range between 0.45 -1.47 µm (54). 
In 2012 Paz, et al., applied the PGSS method 
to produce β-carotene encapsulating proliposomes 
(9). In this study, carbon dioxide was used to 
saturate an aqueous suspension of β-carotene using 
a static mixer at high pressure. First, an emulsion 
was prepared by mixing phospholipid compound 
(lecithin) with water by means of stirring, to obtain 
concentrations of 52, 62, and 72 g/L. Three final 
concentrations of lecithin were used for the 
purposes of a factorial design study. Then β-
carotene was dissolved in dichloromethane (DCM) 
and added to the phospholipid emulsion and further 
homogenised to form a macro-emulsion. An 
evaporation phase using a rotary evaporator was 
conducted to eliminate the organic solvent and 
obtain a solvent free emulsion (9). The prepared 
macro-emulsion was exposed to scCO2 at a flow 
rate of 15 kg/h. Once selected conditions were met, 
the system was depressurised to atmospheric 
conditions within the spray tower, consequently 
generating small dry particles, which collected for 
characterisation. This method formed 
proliposomes with the size 10-500 µm and 
encapsulating efficiency 30 - 60%, which under 
hydration formed liposomes with size 1 - 6 µm (9).  
Data presented by Varona, et al., showed that 
increases of pre-expansion temperature can 
enhance the encapsulating efficiency of lavandin 
oil, similarly, increasing pressure was found to 
promote the encapsulating efficiency (54). While 
increases in the gas to product ratio (GPR), was 
found to have a significant reduction effect on the 
encapsulating efficiency. This was explained by 
the evaporation loss of essential oil during mixing 
SCF and depressurization phases (54). Paz, et al., 
had promising encapsulating efficiencies 
compared to that achieved by Varona, et al., with a 
major difference being higher GPRs (9). It was 
stated that increasing the GPR leads to accelerated 
mass transfer in the mixing phase, thus increasing 
the amount of carbon dioxide that can be dissolved 
in solution, and hence improving atomisation of 
solution to forms particles with better uptake of the 
bioactive.  
The concentration of phospholipid was also 
found to be an important influence on the particle 
size. Varona, et al., (54), found in contrast to Paz, 
et al. (9), that increasing phospholipid 
concentration in the organic solvent (52 - 72 g/L) 
resulted in significant reduction in particles size. 
This was explained due to the co-solvent role for 
phospholipids that enables more carbon dioxide to 
be dissolved with the solution (co-solvent effect) 
leading to enhance atomization (54). This method 
also used the highest flow rate (15,000 g/h) 
compared to the other methods used for 
proliposome preparation. 
 
Supercritical anti-solvent (SAS) process 
The SAS technique may be considered the most 
attractive, as it offers many advantages it terms of 
lower residual solvent content, being a relatively 
simple process, and able to process molecules with 
poor solubility in the SCF as the SCF is used as an 
anti-solvent (20). SAS methods are the most 
commonly reported methods for proliposome 
preparation in the literature. Generally, the API 
molecule is first dissolved in an organic solvent 
and this solution is fed through a tube into another 
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tube housing a SCF. In these methods, the SCF 
plays an anti-solvent role, as the organic solvent 
and SCF mix, the bioactive compound precipitates 
out. This technique exploits the fact that an organic 
solvent can dissolve a large amount of gas by 
forming a mutual miscibility of organic and SCF 
phase, in which the proliposome components 
would precipitate out on exposure to the SCF (49). 
As the organic solvent is diluted in the SCF phase, 
the solutes would form a solid-state proliposome 
which would have API incorporated.  
It is worth mentioning that there are somewhat 
interchangeable terms regarding the way the SCF 
phases are formed. By convention the gas anti-
solvent (GAS) method (presented in more detail in 
the subsequent section) is one where a compressed 
gas is progressively added to a solution containing 
a bioactive and primary solvent until a SCF/dense 
gas state is reached, whereas the SAS method has 
the solution of bioactive and solvent sprayed 
continuously into a SCF or as the case may be, a 
dense gas (near supercritical fluid conditions) (61). 
For the purpose of this review, where it is obvious 
for the SAS method described, it is assumed that a 
SCF state has been achieved, unless otherwise 
stated and the API solution is sprayed continuously 
into the SCF phase. Both the SAS and GAS 
methods use a setup similar to that shown in Figure 
3A. 
Magnan, et al., was the first to implement the 
SAS method to produce proliposomes (38). This 
study was carried out to determine the influence of 
operating pressure, solution flow rate, and solute 
concentration on the generated particles. A 
solution was prepared by dissolving soy lecithin 
S75 (a mixture of various phospholipids, Table 3). 
After the desired temperature and pressure were 
reached, the solution (of ethanol) with a flow rate 
range of 10 - 28 mL/h was introduced into the 
precipitation chamber (500 mL). At steady state 
and within desired operating conditions, a solution 
was sprayed via an atomising capillary (internal 
diameter of 150 µm) into the dedicated 
precipitation chamber forming small droplets of 
solution with co-current stream of scCO2 (flow rate 
400 g/hr) (38). It was found that the high solution 
flow rate enhances the diffusing of SCF to form 
solution droplets, as the solvent is miscible with the 
SCF, thus inducing precipitation of micro-
particles. This method produced dry (residue free), 
spherical proliposomes with size range between 1 
– 40 µm (38). It should be noted that use of an 
atomising capillary (nozzle) allows for the reduced 
solution flow rate. It has been suggested that to 
ensure the formation of droplets out of a capillary, 
the solution must be pumped into precipitation 
chamber with a flow rate of at least 180 mL/h (62). 
This is an important aspect of this SAS method 
compared to other anti-solvent SCF methods 
because without atomising it is more difficult to 
form smaller particles. The remaining SAS 
methods outlined did not reach atomising flow 
rates, however they employed the continuous API 
loaded solution into the SCF phase where the SCF 
acted as an anti-solvent.  
Recently, Liu, et al., implemented the SAS 
method to prepared 10-hydroxycamptothecin 
(derived from camptothecin) loaded proliposomes 
(59). The general experimental set-up was similar 
to that shown in Figure 3 and the parameters are 
listed in Table 3. In brief, solutions of API and 
liposomal components were made with organic 
solvents, to give a final concentration of 1 mg/mL. 
Supercritical CO2 was pumped into the 
precipitation chamber with a constant flow rate of 
20 g/min. After the desired temperature (30-50° C) 
and pressure (80 - 160 bar) was reached, a solution 
was pumped through an injector inlet (also known 
as the expansion capillary) with a constant flow 
rate (0.3 - 1.5 mL/min) into the precipitation 
chamber. Upon precipitation and washing phase 
completion, particles were collected to be 
characterised. The size, shape and API loading of 
the produced particles were influenced of changing 
the mass ratio of lipid components, API 
concentration, and various operating conditions. 
The results from this study showed that 
proliposomes can be formed, which under 
hydration gives spherical, near spherical, and 
clavate shaped liposomes. Under optimisation 
conditions (40° C, 160 bar, solution flow rate 18 
mL/h), the precipitate particles were in the clavate 
shape giving drug loading (DL) of 5.33%, 
entrapment efficiency (EE) of 85.28% and 
relatively narrow particle size distribution with a 
mean diameter (PD50) of 209.8 ± 38.4 nm with an 
acceptable residue limit (ICH guidelines) (59).  
Recently Naik, et al. utilised a SAS method to 
prepare docetaxel encapsulated PEGylated 
liposomes from proliposomes (53). Docetaxel is an 
anticancer agent used in the treatment of a range of 
solid tumours. The solution contained different 
mass molar ratio of bioactive, phospholipids, and 
cholesterol, dissolved in a mixture of organic 
solvents. SCF was pumped into the precipitation 
vessel with constant flow rate (ranging between 2-
7 g/h), after desired and pressure (ranging between 
100 - 220 bar) reached the bioactive containing 
solution was pumped with constant flow rate 9 
mL/h into the precipitation chamber. There is no 
mention about diameter of the nozzle or whether it 
is a capillary or actual nozzle, given the solution 
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rate of only 9 mL/h this may not have been enough 
for atomisation, as will be discussed later and the 
authors have referred to this as a SAS method. 
Nevertheless, due to the simultaneous diffusion of 
SCF into the organic solvent (antisolvent effect), 
small particles (proliposomes) were precipitated. 
Data showed that docetaxel loaded PEGlyated 
proliposomes were successfully formed and with 
hydration produced PEGlyated liposomes with a 
size range between 200 - 300 nm, in spherical and 
small unilamellar shape (53). 
In 2011 Lesoin, et al., applied the ASES 
method to produce proliposomes and then 
liposomes encapsulating lecithin (56). Solution 
was prepared by mixing 2 g of soy lecithin with 
organic solvent (ethanol) to obtained final 
concentration of solute ranging between 15-25 
%w/w. Carbon dioxide was brought to SCF 
conditions and the solution was pumped with a 
flow rate of 22.8 mL/h into the precipitation 
chamber a capillary (diameter 127 µm). The 
precipitation of small particles (proliposomes) 
were collected after CO2 washing and 
depressurization phases to be characterised. 
Results showed that particles distribution size was 
bimodal with two population of particles size 
between 0.1 - 500 µm but the majority of particles 
size ranging between 0.1 - 1µm (56). The 
prolipsomes were hydrated with stirring which 
helped to form a homogenous mixture of 
liposomes. As noted later by the same research 
group, a major drawback of this method was that 
the proliposomes would aggregate (between 
phospholipids) spontaneously upon contact with 
air, so they had to be handled with almost 
impractical precautions before hydration (44). This 
study did not include an API in the preparation of 
the proliposomes and only used a solution flow rate 
of approximately 23 mL/h, rendering atomisation 
unlikely to have been reached. Noting the fact that 
an API was not present as an ingredient, the 
particle size distribution was relatively narrow for 
almost 90% of the particles (0.1 to 1 µm). 
 
Gas anti-solvent (GAS) method 
In this semi-continuous method the experimental 
apparatus is presented in Figure 3A. Apart from the 
progressive addition of the SCF phase into the API 
solution, which is the reverse of the SAS method, 
the GAS unit is composed of two structures; one 
designed to hold the solution of bioactive, 
phospholipid, and sufficient organic solvent to 
dissolve the solutes and this solution is under 
ambient temperature and pressure. While the other 
part is where precipitation takes place, hence this 
part is known as the precipitation chamber. This is 
a dedicated vessel designed to withstand high 
pressure and is housed by a water bath/heat pump 
to reach a desired temperature.  
This process has been conducted in the 
following order; a mixture containing solute is 
dissolved in an organic solvent which is injected 
into the precipitation chamber, carbon dioxide in 
its liquefied state is then pumped into the same 
chamber. The precipitation chamber is pre-heated 
to prevent cavitation prior to the above step. Then 
the precipitation chamber is pressurised and the 
solution:SCF ratio is decreased several fold (63), 
leading to rapid supersaturation, which decreases 
the solvating power of the organic solvent 
drastically, causing nucleation and crystal growth. 
After the precipitation phase, the remaining solvent 
is washed out by pure carbon dioxide to eliminate 
organic solvent traces in precipitate particles, 
which settle on the bottom of the precipitation 
chamber (62). This method offers to produce a 
higher yield of particles compared to the SAS 
method due to the longer residence time in the 
precipitation chamber which can also affect the 
morphology of precipitate particles. 
A modified GAS method developed by Karn, 
et al., in 2013, describes a simpler, innovative, and 
scalable SCF method compared to other liposomal 
preparation methods (8). In this method an 
immunosuppressive API (Cyclosporine A), used a 
highly lipophilic model bioactive, was loaded into 
the liposome’s bilayer to improve drug efficiency 
and stability. A mixture of solute (Cyclosporine A) 
with the liposomal ingredients was dissolved in 
ethanol, this solution was loaded into the 
precipitation chamber accompanied with lactose. 
The carbon dioxide was progressively introduced 
to the precipitation chamber by use of a syringe 
pump. Pressure ranging from 80 to 250 bar and 
temperature ranging from 35 to 50° C was 
investigated in order to find the effects the final DL 
of proliposomes/liposomes. It was found that 
supercritical fluid conditions (temperature 45° C 
and pressure 100 bar), but not subcritical 
conditions, were able to produce multilamellar 
liposomes on hydration. Liposome sizes ranged 
between 0.7 - 1.4 µm, were homogenous, and the 
produced liposomes were physically and 
chemically stable over 14 weeks (8). When 
pressure was kept constant (10 MPa or 100 bar), it 
was observed that temperature had varying effects; 
increasing the operating temperature (40 - 45° C), 
resulted in a higher yield (87.2 - 89.3%) and DL 
increased from 20 to 20.5 %w/w, while increasing 
the temperature further (45 - 50° C), resulted in a 
lower yield (89.3 - 79.7%) and DL dropped from 
20.5 - 18 %w/w (8). The authors claimed that the 
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changing yields and DLs occurred due to the 
different roles of SC carbon dioxide within the 
process, at a lower temperature, the antisolvent role 
can facilitate extraction of the organic solvent from 
solution, and at higher temperatures the SC carbon 
dioxide acts as solvent. The solvent role leads to a 
larger dissolved portion of solute, and hence the 
process yield will decrease drastically, and as a 
consequence DL decreased. Similarly, when 
pressure within the precipitation chamber was 
increased (100- 250 bar), there was a significant 
reduction in yield (87.2 - 42.1 %) and DL (20 - 9.35 
%w/w) (8). Overall, this method produced the 
highest yielding product (up to 89.3%), 
unfortunately neither the solution or CO2 flow rates 
were recorded and the DL was variable. It must be 
noted that this study also utilised some of the 
highest pressures (up to 250 bar) which may help 
explain the high yields observed. 
 
Aerosol solvent extraction system (ASES) 
Another semi-continuous antisolvent method 
called the aerosol solvent extraction system 
(ASES), first developed by Bleich and coworkers 
in 1993, was shown to enhance the mixing between 
the solution and scCO2 and to offer more effective 
control over the size of generating particles (62). 
Instead of a conventional SCF mixing process 
where a solution enters the precipitation chamber 
via a capillary, a solution using the ASES method 
has been introduce into the precipitation chamber 
via a nozzle, to form smaller droplet sizes, 
therefore smaller particles. This is also known as 
the supercritical assisted atomisation (SAA) 
method. This process increases the contact surface 
area between solution and SCF, consequently 
increasing the rate of diffusion of the SCF, hence, 
improve the nucleation process. Essentially, at 
lower flow rates ASES is a better way for 
atomization to occur than by the SAS method. The 
experimental set up is similar to that for SAS and 
GAS except that there is a basic nozzle instead of 
a capillary (injector inlet) (Figure 3B). As noted by 
Bleich, et al. that the nozzle helps to form smaller 
droplets, hence smaller particles, however this 
difference is not so clear at high liquid flow rates 
with capillaries (61). For methylene chloride the jet 
breakup disappears for a capillary of 150 µm and 
flow rate of 180 mL/h, which is when atomization 
is realised (61). Furthermore, the nozzle vs. 
capillary effect may not always matter, as the 
material being investigated is not always affected 
by the SCF conditions/parameters, e.g. polymers 
exposed to variable SCF temperatures and 
pressures seems to have limited effects on particle 
morphology (64).  
In 2006 Kunastitchai, et al., implemented an 
ASES method to form dry microparticles 
containing miconazole (51). The experimental set 
up was described without the use of a diagram but 
it was noted that the spray rate was 180 mL/hr, 
which is what is required to atomise the bioactive 
solution without a nozzle. This study investigated 
the influence several factors, including the solute 
concentration, and surfactant effects on the 
microparticles formed. Two different solution 
concentrations were studied (19 and 38 %w/w) 
mixed with phosphatidylcholine (PC) and 
cholesterol in two different mixing ratios (10:0 and 
8:2 w/w) dissolved in organic solvents (8:2 w/w 
ethanol and methylene chloride) with and without 
Poloxamer 407 (51).  SC carbon dioxide was 
introduced into the precipitation chamber (volume 
of which was not stated), after the pre-set 
temperature and pressure were obtained, solution 
pumped into the precipitation chamber through a 
nozzle (diameter of 0.4 mm and angle of spraying 
was 15⁰) to form small solution droplet within co-
current flow of scCO2, leading to precipitation of 
small particles (51). On drying and washing with 
pure carbon dioxide for 3 to 4 hr the system was 
depressurized, and sample collected for 
characterization. The process produced cubic and 
rod-like shaped particles with some aggregation. 
Complete hydration the solid particles at 55° C 
produced liposomes with particle size range 
between 2.7 – 9.4 µm, which depended on the pH 
of the hydration medium. Generally, those 
hydrated with a higher pH (7.2) possessed larger 
particles with higher EE (51). 
Bridosn, et al., in 2006, applied modified 
version of the ASES method to produce 
phospholipids powders (65). In this study, four 
different solutions (of 10 mL each) composed of 
different phospholipids were dissolved in ethanol 
to obtained a final concentration of 45 mg/mL. The 
solution and scCO2 mixing in the precipitation 
chamber was typical for the ASES method, 
however it was additionally housed in a T-shaped 
assembly within a water bath. The significance of 
which is not known, although it was indirectly 
stated that the T-shaped piece may have affected 
the ethanol expansion, therefore the 
supersaturation rate of the phospholipids on 
contact with the SCF. Once the desired operation 
conditions were reached, solution was sprayed via 
an inlet capillary into T-piece of the precipitation 
chamber. The study also investigated the influence 
of different parameters, such as changing the type 
of lipid (listed previously), solution flow rate (15 - 
30 mL/h), SCF flow rate (between 15 - 20 
mL/min), and the capillary diameter (75 - 150 µm) 
J Pharm Pharm Sci (www.cspsCanada.org) 18(5) 747 - 764, 2015 
 
 
 
757 
(65). This method obtained fined particles with 
diameter size range between 1 - 3 µm and these 
proliposmes under hydration produced liposomes 
with size ranging between 1 - 10 µm. The down 
side to this study was that the resulting liposomes 
are considered to be too big for use as a drug 
delivery system. It was suggested that larger sized 
liposomes can be used to facilitate encapsulating 
poor-water API intended to be administered orally 
(65).  
 
Solution enhanced dispersion by supercritical 
fluids (SEDS) 
This technique was first developed by Hana and 
York in 1994 at Bradford University, UK (52). 
This research received a patent essentially on the 
use of a coaxial nozzle along with the other SAS 
method parameters. The solution enhanced 
dispersion by supercritical fluid or SEDS offers 
several advantages over other SAS methods, in 
terms of being agglomeration free, having a shorter 
drying time, more readily scalable, can achieve 
small particles size using lower solution flow rates 
(less than 180 mL/hr). A reduced washout phase 
time period can also eliminate traces of solvent 
residues within particles. Experimental setup for 
this approach is slightly different from ASES and 
other SAS methods in that the coaxial nozzle 
(double or triple component) is used as the entering 
route for both bioactive solution and the 
supercritical fluid, see Figure 3C.  
In a study by Xia, et al., using the anti-solvent 
method (SEDS), lutein and hydrogenated soya 
phosphatidylcholine (HPC) was dissolved in a 
mixture of dichloromethane and ethanol (ratio 40:1 
v/v) with a final concentration of 0.73 mg/mL (55). 
Carbon dioxide was liquefied and then pumped 
into a 200 cm3 precipitation chamber via a coaxial 
nozzle (inner diameter 0.2 mm) and the lutein 
solution was introduced at a constant flow rate of 
60 mL/hr (55). The coaxial assembly allows for the 
rapid mixing of scCO2 and solvent leading to a 
rapid decrease in the solvating power of organic 
solvent, simultaneously the lutein reaches 
supersaturation equally rapidly, resulting in 
precipitation of proliposomes in the precipitation 
chamber. Investigated values for pressure with 
precipitation chamber ranged between 80 - 120 
bar, with temperatures between 35 - 55° C. The 
optimization process demonstrated the highest DL 
was obtained with a pressure of 80 bar and a 
temperature of 35⁰C. In was also found that an 
increased pressure from 80 - 120 bar by the SCF 
during precipitation favoured the formation of 
smaller proliposome particles. This SEDS method 
produced spherical particles with size around 200 
nm and narrow PDI, lutein was successfully 
embedded into proliposomes with loading 
efficiency reached to 55.04 mg/g (55). In another 
study by Xia, et al., in 2011 using a similar 
preparation method as above, it was found that 
after the hydration, the formed liposomes 
encapsulating vitamin D3  had a size of range of 
between 1 - 2.7 μm (57). The proliposomes are 
reportedly easily hydrated, forming unilamellar 
liposomes with entrapment efficiency for both 
studies reaching within the 90% region.  
In a subsequent study, Xia, et al., implemented 
the SEDS method again to prepare Coenzyme Q10 
(CoQ10) encapsulated proliposomes (58). The use 
of proliposomes and ultimately liposomes was a 
strategy used to overcome the solubility difficulties 
exhibited by CoQ10, which is considered a ‘brick 
dust molecule’ with poor aqueous solubility and 
poor absorption through biological tissues. In brief, 
a solution was prepared by mixing the bioactive 
with phosphatidylcholine (PC) between ratios of 
1:10 and 2:10 (w/w), to which cholesterol was 
added within range ratio of 1:1 and 1:3 (w/w). 
These compounds were dissolved in an organic 
solvent mixture (dichloromethane and ethanol 
13:12 v/v) to obtained solute concentration of 1.8 
mg/mL.[58] SC carbon dioxide was pumped into a 
200 cm3 precipitation chamber via a coaxial nozzle 
as used previously, the solution had a flow rate of 
60 mL/h (58). The investigated parameters 
included the pressure range between 80 - 160 bar 
and temperature range between 35 - 55° C for 
temperature. The findings for optimised 
parameters were T= 35° C and P = 80 bar, weight 
ratios 1:10 between CoQ10 and PC, and 1:3 
between cholesterol and PC (58). Data from this 
study demonstrated that the SEDS technique can 
be used to produce proliposomes that under 
hydration can form liposomes with an estimated 
size of 50 nm. 
The operating temperature during SEDS 
processing influences the parameters of the final 
product. With increasing operating temperature, 
DL percentage decreased (55, 58). This 
phenomenon can be explained thermodynamically 
as increases in the system temperature leads to 
reducing anti-solvent capacity of scCO2, thus 
partial reverse extraction back to the solvent 
occurs, as consequence yield and DL decreases 
(58). The effect of temperature on yield was 
investigated by Kunastitchai, et al., and it was 
shown that decreasing temperature promoted 
higher yields (39). It was suggested that 
temperatures above the glass transition point for 
the phospholipids studied is avoided, which is 
approximately 51° C (51). In contrast Naik, et al., 
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found no significant influence by temperature on 
particles size but found a significant reduction on 
yield, as temperature increased to 46º C, the yield 
dropped to 23.6% (53). These findings were 
consistent with that observed by Liu, et al. (58). 
The influence of pressure under the SAS-
SEDS methods examined by Xia, et al. (55, 57, 
58). found that higher DL can be achieved with 
lower pressure (80 bar), which was explained by 
the authors as a result to the relatively low 
concentration of scCO2 within the precipitation 
chamber, leading to partial solvent extraction, thus 
effecting the time to reach the supersaturation 
point, and as a consequence reducing the DL level. 
These finding for suppression of the yield and DL 
at lower pressures is thermodynamically 
consistent, since increasing pressure (i.e. amount 
of SCF present) would lead to the supersaturation 
point quicker, resulting in a higher yield and DL. 
In addition Kunastitchai, et al., suggests that higher 
yield can be obtained at higher pressure values, 
provided the SCF phase has a density of more than 
0.3 g/mL (for carbon dioxide this can be achieved 
at 80 bar) (51). A similar pressure influence was 
found by Liu, et al., were a positive influence 
occurred on entrapment efficiency, particle size, 
and drug loading (59). In contrast, data presented 
by Lesion, et al. (56) had shown that pressure has 
no significant influence of the micropartciles and 
their morphology, which was consistent with the 
data by Reverchon, et al., where pressure did not 
have a dramatic influence on the formation of 
solid-lipid particles (66). This was also agreed by 
Bleich, et al. who studied the influence of gas 
density and pressure (67). The study by Naik, 
et al., showed that pressure had a significant 
influence on the particles size and the yield (53). 
These findings have been further confirmed by 
Magnan, et al., that as pressure increases from 80 
to 110 bar there was no significant influence on the 
size and morphology of phospholipids formed 
(38).  
The effect of solute concentration across the 
SAS studies examined showed positive linear 
relationships between increasing concentration and 
yield and DL. Lesion, et al. noted that an increasing 
of lecithin concentration, lead to bigger particles 
size (30 - 60 µm) and more distinct spherical 
particles (56). These findings were consistent with 
that in the earlier work by Reverchon, et al., where 
it was established that higher concentrations of 
solute lead to early precipitation during expansion 
and the growth is the predominant mechanism for 
producing bigger particles (66). Kunastatchai, et 
al., also noted that increasing solute concentration 
produced cubic and rod-like shape crystals, which 
was explained as a result of the linear relationship 
between concentration of the solute and solution 
viscosity (51). As the solute concentration 
increases the atomisation force may not be 
sufficient to break-up the solution to form droplets, 
as a consequence larger particles form. Magnan, et 
al., observed a similar result, where decreasing the 
solute concentration led to fine particles being 
formed, which made sense even when the solution 
injection rate was increased, so too did the particle 
size (38). At relatively low solution flow rate (10 
mL/h) the particles were fine powders, while at 
higher flow rate 28 mL/h produced bigger particles 
(38). One way to be able to reduce the flow rate 
and still achieve atomisation is through the use of 
a nozzle with a spray angle. It has been stated that 
a capillary (zero angle) requires much higher flow 
rates to reach atomisation from a SCF dispersed 
phase (52, 61). Figure 4 shows the different spray 
angles that can be created simply by using different 
spray nozzles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Nozzle and spray angles from capillary (0) to 40 degrees Celsius. 
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The effects of atomisation and solute 
concentration are important and need to be 
considered when determining the SCF method 
parameters for a SAS type experiment. It should be 
noted that most SCF research has used closed 
systems, that is it is not possible to observe SCF 
related phenomenon, such as atomisation during 
precipitation and solubility of a solute in a SCF. 
Furthermore, many of the observational studies 
that have investigated flow dynamics through a 
nozzle or capillary to determine atomisation used 
shadow-based optical methods that cannot actually 
detect differences between droplet or dense gas 
forming sprays. As noted by Reverchon, et al., this 
is because both the droplet fill spray and dense gas 
spray or “gas-plume” are visualised as a dark 
shadow, making it difficult to differentiate between 
them (64). As also noted by Reverchon, et al. 
specialised light-scattering equipment is required 
to make diagnostic statements and definitively 
decide between atomised droplets and dense “gas-
plume”. Solubility studies must be considered also, 
and this is important because of SCF phenomenon 
such as the crossover region where lower 
temperature at a given pressure can result in a 
higher solubility of a solute (50). Solvent density 
and solute volatility are responsible for the 
crossover region of a SCF and it has implications 
for retrograde re-crystallization. This particular 
effect becomes even more complicated when 
investigating complex mixtures such as 
pro/liposomes that have multi-components. In a 
simple binary system, there are only the solute-
solvent interactions that can affect solubility. 
Whereas for systems with 4 or more components 
(e.g. phospholipids, cholesterol, drug, SCF, and 
possibly a polymer and co-solvent), there are 
multiple solute-solvent interactions, along with 
separate solute-solute interactions. Therefore, 
determining the lower and upper crossover points 
and critical mixture pressure (CMP) for such multi-
component systems needs to be a fundamental part 
of  research in SCF technologies and preparation of 
advanced pharmaceutical delivery systems.  
 
A suitable SCF method for proliposome 
preparation 
To date there are only 12 articles written on the use 
of SCFs in the preparation of proliposomes, with 
the first published by Magnan et al. in 2000 (38). 
This reflects the unrealised potential of PLs as drug 
delivery systems. As described elsewhere, a 
breakthrough is more difficult if only academic 
research is developing new methods (68).  
From the methods outlined, the SCF chosen 
was partly to do with the suitability with the 
physico-chemical properties of the API, that is the 
API solubility in the selected SCF, the SCF unit 
operating limits, and probably a consideration of 
SCF conditions and effects on the excipients used 
(e.g. not exceeding 60° C in order to preserve lipid 
or protein integrity). What determines the SCF 
solubility is not clearly understood but as a guide 
for scCO2 the smaller nonpolar molecules (less 
than 500 Daltons) are more easily dissolved at 
moderate pressures (41). While for larger 
molecules there is poor scCO2 solubility for 
pressure less than 500 bar. The term “CO2-philic” 
has been used to designate whether a molecule is 
miscible at a given concentration and pressure. 
Also the more volatile (lower melting and boiling 
points), the more miscible the material will be in 
scCO2. Also the SCF conditions may favour certain 
excipients such as charged lipids, which are more 
aqueous soluble, therefore the use of a polar SCF 
such as DME or nitrous oxide would be more 
suitable. The selection of the SCF is an important 
step in the designing the most suitable SCF method 
in the preparation of a proliposome. It is also 
desirable to have research focused on the use of 
SCF solvent methods, that is the non-organic 
solvent dependent SCF methods, as the need to 
have environmentally friendly pharmaceutical 
manufacturing becomes more and more of a 
regulatory standard. 
To date, SCF methods have not been well 
defined and the published methods are often 
difficult to follow and understand. Moreover, 
scale-up challenges exist such as safety in the 
handling of SCF and liquefied gases, plugging 
issues where solid-fluid equipment use closed 
systems, disk rupture results from brutal 
depressurisation, and tubing connection failure, 
where commonly used  tubes on the small-scale are 
safe and reliable may not be suitable on larger 
scales (69). Fortunately, most of these may be 
challenges can be overcome, but caution and 
research is required to ensure there are no issues 
with the final setup and operation of SCF 
equipment. Some ideas focus on the use of 
automation, fluid management including 
recycling, and maintenance processes in the case 
where metal fatigue and carbon steel may be 
corroded (69). Where SCF prepared proliposomes 
have almost certain advantages in the delivery of 
anti-cancer agents. Once hydrated into liposomes 
ready for administration, there are improved 
pharmacokinetic outcomes (e.g. prolonged 
resident time) and reduced adverse-effect (e.g. 
avoiding phlebitis during IV injection for 
chemotherapy) (70). From the literature, there is 
already a slight preference towards anti-cancer 
J Pharm Pharm Sci (www.cspsCanada.org) 18(5) 747 - 764, 2015 
 
 
 
760 
agents, molecules that are large (> 500 g/mol), and 
poorly water soluble, as well as cancer 
preventative anti-oxidant agents. Another major 
advantage is in terms of stability, compared with 
conventional liposomes, SCF produced liposomes 
offer a dry liposome powder to be directly 
obtained, without the need to conduct further 
processing, such as spray-drying, precipitation, or 
freeze drying (71). 
 
CONCLUSION 
 
Proliposomes prepared by SCF processing for 
pharmaceutical drug delivery is an emerging 
technology. The use of proliposomes overcomes 
the major drawbacks of liposomes in terms of 
chemical and physical stability on storage and SCF 
technologies provide alternative methods to 
produce proliposomes. To date, most of the studies 
have utilised the anti-solvent process. However, 
this should not be an indication that the anti-
solvent methods are superior to the solvent 
methods and it is the SCF solvent methods that 
must drive the future of pro/liposome preparation. 
SCF methods to prepare proliposomes are 
promising alternatives to the existing conventional 
methods, the SCF solvent methods being green 
technology, with reduced and even eliminated 
organic solvent reliance, and high processing 
efficiency. Research needs to be focused on the 
non-organic solvent SCF methods, taking into 
account the API properties and lipid ingredients to 
form proliposomes. Further research is required to 
address some limitations and to make the 
production more predictable and industry ‘ready’ 
and importantly GMP compliant.  
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Table 4. Current research on preparation of proliposomes using various supercritical fluid technologies. 
Method  
used 
Temperature/ 
pressure 
(° C/bar) 
Ingredients/Solvents Bioactive (drug 
loading, %w/v) 
Solution 
flow rate 
(mL/h) 
CO2  
flow rate 
(g/h) 
Particle size  
range (µm) 
(morphology) 
Yield 
(%) 
Drug 
Loading 
(%) 
Year Ref 
SAS/GAS 35/ 
80 -110 
PC/phosphatarolamine 
2% ethanol 
API/drug free 10 – 28 400 1-40 
(spherical) 
NR NA 2000 (38) 
ASES 31 -60/ 
85 -105 
PC/chol/poloxamer 407 
methylene chloride 
 
miconazole 
(19 & 38) 
180 6000 2.7-16.2 
(cubic/rod-like) 
50-70 NR 2006 (51) 
ASES/T-piece 
assembly 
20 -55/ 
150 -250 
PC/DMPC/DPC/ 
Chol/7% ethanol 
API/drug free 15-30 540 –  
2580 
1-3 (cubic/ 
acicular) 
NR NA 2006 (52) 
SAS 34 -46/ 
100 -220 
hydrogenated PC/ 
DGPE/Chol/PEG2000/ 
chloroform:methanol, 2:1 
docetaxel 9 1800–7200 
 
0.27 ± 0.003 
(NR) 
37.5 
±4.5 
23.6-67.5 2010 (53) 
PGSS 20 -120/ 
10 -120 
soybean lecithin  
(97% phospholipids)/ 
Chol/chloroform 
lavandin NA 15000 1.4 -24.8 NR 2.7 -14.5 
liposome 
2011 (54) 
SEDS 35 -55/ 
80 -120 
hydrogenated PC/  
ethanol 
vitamin D3 30 6000 0.3 -0.6 
(irregular spheres) 
NR 3.62- 
12.89 
2011 (55) 
ASES 35/ 
90 -130 
soy lecithin (71% PC)/ 
Chol/ethyl alcohol 
API/drug free 
 
22.8  0.1-1 (89.3%) NR NA 2011 (56) 
SEDS 35 -50 
80 -160 
hydrogenated PC/ 
ethanol:dichloromethane 
Lutein 
(0.73) 
30-90 1800 0.2 
(spherical) 
NR 55.5 2012 (57) 
SEDS 35 -55 
80 -160 
PC/Chol/ 
ethanol:dichloromethane
coenzyme Q10 
(1.8)
60 1.7m3/h NR NR 8.9 2012 (58) 
PGSS 102 -123/ 
81 -102 
Soybean lecithin/ 
dichloromethane 
beta-carotene 
(6.2-7.2) 
NA 1500 10 – 500 19.2- 
44.9 
34.4- 
58.7 
2012 (9) 
GAS 35 -50/ 
80 -250 
egg PC/lactose anhydrous/ 
ethanol 
cyclosporin A 
(2) 
NR NR 0.97 – 1.53 42.2- 
89.3 
9.4 –  
20.5 
2013 (8) 
SAS 30 -50/ 
80 -160 
soy lecithin/cholesterol/ 
dimethyl sulfoxide 
10-hydroxy 
camptothecin 
18-90 1200 0.21 ± 0.04 NR 5.33 2014 (59) 
Key: SAS = supercritical anti-solvent, GAS = gas anti-solvent, ASES = aerosol solvent extraction system, PGSS, particles from gas saturated solution, SEDS = solvent enhanced dispersion 
from supercritical fluid, PC = Phosphatidylcholine, DGPE = disteroyl glycerol phosphatidyl ethanolamine, DPC = distearoyl phosphatidylcholine, DMPC = dimyristoylphosphatidylcholine, 
Chol = cholesterol, NA = not applicable, NR = not recorded. 
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 Figure 3. A) Basic apparatus setup for the supercritical anti-solvent (SAS) and gas anti-solvent (GAS) methods, B) the experimental setup for the aerosol solvent extraction system (ASES) 
method, C) the apparatus for the solvent enhanced dispersion from supercritical fluid (SEDS) method. The different possible nozzle structures are shown (a) is a two component coaxial and (b) 
is a three component coaxial design, and D) the experimental setup for the particles from gas saturated solution (PGSS) method. Liquid CO2 is given as the example. Jet break-up existence and 
lengths are for conceptual aid only.
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